Drug intelligence / Profile preview

nnc9204-1513

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Subcutaneous

Overview

NNC9204-1513 (also known as NN9513 or HypoPen 1513) is a subcutaneously administered glucagon receptor agonist developed by Novo Nordisk for the rescue treatment of severe hypoglycemia. It is designed as an easy-to-use injectable product for emergency management of low blood sugar episodes. The drug acts by stimulating the glucagon receptor to rapidly increase blood glucose levels through hepatic glycogenolysis and gluconeogenesis. As of the latest available information, NNC9204-1513 has completed phase I clinical trials but has not advanced further in development or reached the market[1][2][3].

Brand names: HypoPen 1513HypoPen1513HypoPen-1513
Other names: NNC9204 1513NNC-9204 1513NNC 9204 1513NN9513NN-9513NN 9513

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on nnc9204-1513.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nnc9204-1513.

Explore the full profile